Oppenheimer raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $60.00 (from $55.00) while maintaining a Outperform rating.Analyst Jay ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Neurocrine Bio. (NBIX) PT Raised to $100 at H.C. Wainwright on Positive Survey DataFebruary 16, 2017 7:47 AM Needham & Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX) Ahead of 2017 CatalystFebruary 15, 2017 7:58 AM Baird Reiterates Outperform Rating and $66 PT on Neurocrine Biosciences (NBIX) Following 4Q ResultsFebruary 15, 2017 5:56 AM